KCT0007117
Active, not recruiting
未知
A 12 week, Double-blind, Randomized, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of L. curvatus HY7601 and L. plantarum KY1032 on Reducing body weight and body fat on Overweight or Obesity subjects
Vievis NAMUH Hospital0 sites72 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Endocrine, nutritional and metabolic diseases
- Sponsor
- Vievis NAMUH Hospital
- Enrollment
- 72
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Subjects who are adult men and women between 20\~65 years of age
- •2\) BMI of visit 1,2 is placed on 23 kg/m2\~35 kg/m2
- •3\) Subjects who agree the particpation in the trial and submit informed and consent before the beginning of the trial.
Exclusion Criteria
- •1\) Patients with uncontrolled hypertension (over 160 / 100mmHg, after 10 minutes of stabilization)
- •2\) Diabetic patients taking fasting blood glucose levels greater than 126 mg / dl, randomized blood glucose levels greater than 200 mg / dl, or taking oral hypoglycemic agents or insulin
- •3\) subject currently being treated for severe cardiovascular, immune, respiratory, hepatobiliary, renal and urinary, nervous, musculoskeletal, psychiatric, infectious diseases and malignancies.
- •4\) subject who has clinically clear risk factors for gastrointestinal bleeding, or those who are judged by the investigator to have other bleeding tendencies
- •5\) subject who has been diagnosed with or treated for cancer within 5 years of visit 1
- •6\) Drugs that affect body weight Within 1 month based on visit 1(including absorption inhibitors and appetite suppressants, health functional foods / supplements related to obesity improvement, psychiatric drugs such as depression, beta blockers, diuretics, birth control pills, steroids, Who are taking medicines to treat hyperlipidemia
- •7\) Subject who has administered antibiotics or immunosuppressants within 2 weeks of visit 1
- •8\) Subject who has consumed probiotics and lactobacillus products continuously (4 or more times a week) within 2 weeks of visit 1
- •9\) Subject who has had a weight change of 10% or more within the last 3 months
- •10\) Subject who has participated in a commercial obesity program in the past 3 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A 12 week, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of EDL on DyspepsiaDiseases of the digestive systemKCT0005229ovaKmed100
Completed
Not Applicable
Placebo-Controlled Clinical Trial of Efficacy and Safety of MC01 on the Skin Wrinkle Improvement and MoisturizingDiseases of the skin and subcutaneous tissueKCT0007499Maeil Health Nutrition100
Completed
Not Applicable
A 12 Week, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of NVP-2106 on improvement of Cognitive FunctioKCT0009187VP Healthcare120
Active, not recruiting
Not Applicable
The Efficacy and Safety of MKC on the Skin Wrinkle Improvement and MoisturizingKCT0006416Holistic Bio100
Completed
Not Applicable
A 12 week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of Lactobacillus plantarum LMT1-48 on Reducing Body FatEndocrine, nutritional and metabolic diseasesKCT0008055Global Medical Research Center120